MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

180.17
+6.12
+3.52%
Opening 11:07 09/20 EDT
OPEN
172.11
PREV CLOSE
174.05
HIGH
191.67
LOW
171.50
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
249.42
52 WEEK LOW
131.47
MARKET CAP
9.30B
P/E (TTM)
-18.1217
1D
5D
1M
3M
1Y
5Y
New CEO At Mirati Therapeutics
Benzinga · 1h ago
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
Benzinga · 1h ago
Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards
Benzinga · 1h ago
Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO
Benzinga · 1h ago
Hot Stocks: Chinese stocks fall; LI lowers deliveries guidance; MRTX, SPPI data
The major U.S. equity averages saw significant weakness in Monday's pre-market trading, led lower by a drop in Chinese stocks. JD.com, Inc. (NASDAQ:JD), Alibaba (NYSE:BABA) and Baidu (NASDAQ:BIDU) were among
Seekingalpha · 2h ago
BRIEF-Mirati Therapeutics Announces Long-Term Survival Results From Analysis Of Sitravatinib Plus Nivolumab
reuters.com · 2h ago
Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors
/PRNewswire/ --  (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500. Results showed durable responses and long-term survival with in combination with nivo...
PR Newswire - PRF · 2h ago
BRIEF-Mirati Therapeutics Appoints David Meek As CEO, Effective Immediately
reuters.com · 3h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRTX. Analyze the recent business situations of Mirati through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRTX stock price target is 216.18 with a high estimate of 300.00 and a low estimate of 160.00.
EPS
Institutional Holdings
Institutions: 314
Institutional Holdings: 62.27M
% Owned: 120.63%
Shares Outstanding: 51.62M
TypeInstitutionsShares
Increased
87
5.70M
New
38
838.97K
Decreased
89
5.29M
Sold Out
52
1.47M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.70%
Pharmaceuticals & Medical Research
-0.67%
Key Executives
Chairman/Director
Faheem Hasnain
President/Chief Executive Officer/Director
Charles Baum
Chief Operating Officer/Executive Vice President
Daniel Faga
Executive Vice President/Chief Scientific Officer
James Christensen
Executive Vice President
Benjamin Hickey
Independent Director
Bruce Carter
Independent Director
Julie Cherrington
Independent Director
Aaron Davis
Independent Director
Henry Fuchs
Independent Director
Craig Johnson
Independent Director
Maya Martinez-Davis
Independent Director
Shalini Sharp
No Data
  • All
  • Financials
  • Insiders
More
About MRTX
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.

Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRTX stock methods without spending real money on the virtual paper trading platform.